Arrowhead Projects $73.8M Q2 Revenue, Gains ARO-PNPLA3 License and Australian Approval
Arrowhead projects $73.84 million revenue and –$1.11 EPS for Q2. It secured a license for ARO-PNPLA3 with Madrigal, reported up to 46% liver fat reduction, and gained Australian approval for REDEMPLO, while holding a debt-to-equity ratio of 0.55 and current ratio of 3.38.
1. Q2 Revenue and EPS Forecast
Arrowhead forecasts $73.84 million in Q2 revenue alongside an expected –$1.11 earnings per share loss, reflecting continued investment in its RNAi pipeline and R&D activities.
2. Madrigal Licensing Agreement
The company struck an exclusive license deal for ARO-PNPLA3 targeting MASH treatment, with early clinical data showing up to 46% liver fat reduction after a single dose, accelerating its development timeline.
3. Australian Approval for REDEMPLO
Arrowhead received regulatory clearance in Australia for REDEMPLO (plozasiran) to lower triglycerides in adult familial chylomicronemia syndrome patients, opening a new market channel.
4. Financial Health and Valuation
The balance sheet shows a 0.55 debt-to-equity ratio and a 3.38 current ratio, while valuation multiples include a P/E of 54.8, P/S of 10.16 and EV/S of 10.26, indicating strong liquidity amid high growth expectations.